{"links":{"html":"https://www.erudio.com/reports/icarus-lung01-nct04940325","json":"https://www.erudio.com/reports/icarus-lung01-nct04940325.json","markdown":"https://www.erudio.com/reports/icarus-lung01-nct04940325.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"icarus-lung01-04940325"}},"request":"https://www.erudio.com/contact?report=icarus-lung01-04940325"},"offer":{"cited_commentary_sources":25,"verified_hcp_statements":59,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":14,"optional":true,"price_per_verified_person_usd":15,"price_usd":210,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"icarus-lung01-nct04940325"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=icarus-lung01-04940325","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/icarus-lung01-nct04940325","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-31T07:37:10.413543Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":14,"no_commentary_found":0},"aspects":[{"claim_count":10,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":8,"title":"Primary endpoint: Evaluation of objective response rate (ORR) based on investigator assessment"},{"claim_count":12,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":7,"title":"Secondary endpoints"},{"claim_count":12,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":9,"title":"Population and setting"},{"claim_count":10,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":3,"title":"The comparison"},{"claim_count":6,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":6,"title":"Safety and tolerability"},{"claim_count":13,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":9,"title":"Design and conduct"},{"claim_count":10,"coverage":"discussed","id":"A1","source_count":9,"title":"Histology-dependent activity and the value of replication"},{"claim_count":9,"coverage":"discussed","id":"A2","source_count":8,"title":"TROP2 expression, H-score and treatment selection"},{"claim_count":7,"coverage":"discussed","id":"A3","source_count":6,"title":"Genomic enrichment versus absent predictive alterations"},{"claim_count":11,"coverage":"discussed","id":"A4","source_count":5,"title":"Resistance mechanisms and longitudinal evidence"},{"claim_count":7,"coverage":"discussed","id":"A5","source_count":5,"title":"Later-line positioning, alternatives, sequencing and tissue work-up"},{"claim_count":2,"coverage":"discussed","id":"A6","source_count":1,"title":"Regulatory expectations and the evidentiary threshold"},{"claim_count":10,"coverage":"discussed","id":"A7","source_count":7,"title":"Appraisal of the translational research model"},{"claim_count":9,"coverage":"discussed","id":"A8","source_count":2,"title":"Antibody targeting, payload effects and biomarker uncertainty"}],"counts":{"cited_sources":25,"claims_by_expression_type":{"comparison":10,"interpretation":18,"opinion":10,"primary_context":2,"question":3,"restatement":6,"uncertainty":6,"unspecified":4},"claims_by_kind":{"source_observation":59},"clinician_statements":31,"evidence_units":49,"findings":8,"organisational_accounts":3,"people_cited":16,"people_identity_verified":14,"people_total":18,"screened_sources":55,"verified_claims":59},"findings_index":[{"id":"F1","structure":{"claims":13,"claims_by_group":{"comparisons":5,"experience":0,"questions":0,"restated":2,"views":6},"has_counterview":true,"limitations":3,"links":{"context":0,"support":14},"ma_question":true,"named_voices":8,"passages":11,"sources":9,"sources_by_kind":{"commentary":8,"media":1}},"title":"Histology shapes the efficacy reading, but replication is not universally viewed as new information"},{"id":"F2","structure":{"claims":8,"claims_by_group":{"comparisons":2,"experience":0,"questions":1,"restated":4,"views":1},"has_counterview":true,"limitations":3,"links":{"context":1,"support":9},"ma_question":true,"named_voices":6,"passages":9,"sources":8,"sources_by_kind":{"commentary":7,"media":1}},"title":"Two speakers emphasize toxicity despite targeted delivery"},{"id":"F3","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":3,"views":3},"has_counterview":true,"limitations":3,"links":{"context":0,"support":8},"ma_question":true,"named_voices":6,"passages":8,"sources":7,"sources_by_kind":{"commentary":6,"media":1}},"title":"TROP2 expression is interpreted as predictive, weakly associated or potentially threshold-dependent"},{"id":"F4","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":1,"views":5},"has_counterview":true,"limitations":3,"links":{"context":0,"support":7},"ma_question":true,"named_voices":6,"passages":7,"sources":6,"sources_by_kind":{"commentary":5,"media":1}},"title":"Genotype-enrichment hypotheses coexist with negative predictive-marker assessments"},{"id":"F5","structure":{"claims":8,"claims_by_group":{"comparisons":1,"experience":0,"questions":3,"restated":3,"views":1},"has_counterview":true,"limitations":3,"links":{"context":3,"support":9},"ma_question":true,"named_voices":5,"passages":10,"sources":6,"sources_by_kind":{"commentary":5,"media":1}},"title":"An undefined later-line role raises sequencing, alternative-treatment and tissue-work-up questions"},{"id":"F6","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":0,"views":1},"has_counterview":true,"limitations":2,"links":{"context":0,"support":2},"ma_question":true,"named_voices":2,"passages":2,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Conditional approval optimism meets explicit dissent about evidentiary standards"},{"id":"F7","structure":{"claims":16,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":1,"views":14},"has_counterview":true,"limitations":3,"links":{"context":0,"support":16},"ma_question":true,"named_voices":6,"passages":14,"sources":10,"sources_by_kind":{"commentary":9,"media":1}},"title":"The translational model is praised, with sample attrition limiting what it can answer"},{"id":"F8","structure":{"claims":10,"claims_by_group":{"comparisons":2,"experience":0,"questions":3,"restated":1,"views":4},"has_counterview":true,"limitations":3,"links":{"context":6,"support":11},"ma_question":true,"named_voices":2,"passages":5,"sources":2,"sources_by_kind":{"media":2}},"title":"The connected ADC discussion questions whether target expression captures payload biology"}],"medical_affairs_question":"What evidence would justify histology- and biomarker-informed selection, sequencing or alternative-treatment choices without overstating the efficacy or understating toxicity?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Histology shapes confidence more clearly than it establishes new benefit"},{"id":"section-2","level":2,"title":"Toxicity qualifies favorable efficacy and safety language"},{"id":"section-3","level":2,"title":"TROP2 association is not a settled selection rule"},{"id":"section-4","level":2,"title":"Genomic enrichment remains exploratory beside negative association findings"},{"id":"section-5","level":2,"title":"Later-line positioning includes alternatives, sequencing and tissue constraints"},{"id":"section-6","level":2,"title":"Approval hope meets dissent about the evidence threshold"},{"id":"section-7","level":2,"title":"A praised translational model still faces longitudinal evidence limits"},{"id":"section-8","level":2,"title":"Target biology may not capture payload response"},{"id":"section-9","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, na, single group, phase2","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":3},{"id":"F4","shared_claims":3},{"id":"F5","shared_claims":2},{"id":"F7","shared_claims":1}],"id":"T1","label":"Primary endpoint: Evaluation of objective response rate (ORR) based on investigator assessment"},{"findings":[{"id":"F1","shared_claims":6},{"id":"F2","shared_claims":5},{"id":"F3","shared_claims":4},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":1},{"id":"F7","shared_claims":1}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F4","shared_claims":3},{"id":"F5","shared_claims":5},{"id":"F7","shared_claims":1}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":7},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":1},{"id":"F7","shared_claims":2}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":6},{"id":"F3","shared_claims":3},{"id":"F4","shared_claims":1}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":1},{"id":"F7","shared_claims":8},{"id":"F8","shared_claims":1}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-31T07:37:10.413543Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-31T07:50:04Z","record_hash":"c731d41c3afaa7ed3c79ade58e605dd88c576427ca4b7b251d1305a1305a918e","release_hash":"aaa5f92eedb9cefd0b4d0abd0314c226c7132ebcbface68df54030175de887d6","report_id":"erudio-nct04940325","run_id":"c3ff1dad-5bef-4dd5-a9a5-8206c93b6dbe","schema_version":"5.0","slug":"icarus-lung01-04940325","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"ICARUS-LUNG01 asks whether datopotamab deruxtecan shrinks tumors in previously treated advanced non-small cell lung cancer and which biomarkers could guide treatment. Commentary comes from X posts, a podcast featuring a medical oncologist, and a YouTube discussion. The discussion turns on datopotamab deruxtecan’s unresolved later-line role, whether target expression captures ADC payload biology, and how to weigh toxicity despite targeted delivery. The sources place the ICARUS-LUNG01 phase 2 results at ASCO 2024.","meta_description":"55 sources screened · 59 verified statements (31 from clinicians verified by NPI or staff page) from 25 sources · 8 findings. Updated Oct 31, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-794e4654126f681813d7"],"id":"F5","paraphrase":"An X post addressed the positioning of datopotamab deruxtecan in nonsquamous NSCLC following immunotherapy and chemotherapy.","publication_caveats":{"reason":"Publication caveats are not stated in the sources reviewed for this edition.","status":"not_set"},"source_channel":"x_thread","source_date":"2024-05-31","title":"An undefined later-line role raises sequencing, alternative-treatment and tissue-work-up questions"},{"cited_claim_ids":["claim-c16d29b9c06ee5ab9cd9"],"id":"F7","paraphrase":"An X poster, described in the source as presenting ICARUS-LUNG01, addressed the study’s role in understanding ADCs.","publication_caveats":{"reason":"Publication caveats are not stated in the sources reviewed for this edition.","status":"not_set"},"source_channel":"x_thread","source_date":"2024-09-15","title":"The translational model is praised, with sample attrition limiting what it can answer"}]},"publication":{"approved_at":"2026-10-31T07:50:04Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":55},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on antibody–drug conjugate efficacy and safety in heavily pretreated non-small cell lung cancer.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","37 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed are selected public discussions, not a representative sample of HCP opinion. Source totals and repost activity cannot be interpreted as numbers of independent clinicians or the prevalence of a view.","Relevant commentary may be missing when it does not use the trial identifier or familiar study-name variants. Some potentially relevant passages were not fully evaluated, and additional presentation summaries are not represented.","Some authors remain unnamed, and several video remarks cannot be assigned to a named participant. They cannot establish additional independent endorsements or disagreements.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","Descriptions of presenting or involvement in ICARUS-LUNG01 are attributed source descriptions, not independently confirmed trial roles. Such appraisals should not be counted as external validation.","Full protocol and exact-trial publication text were not available. Linked article descriptions provide qualitative context rather than a full evaluation of methods, results or mechanistic analyses.","No exact DS-1062a regulatory label was available. Predictions and criticism about approval do not establish an agency decision or current regulatory status.","Reported response proportions differ between sources, and one presentation relay does not identify its PFS comparator. These differences cannot be resolved from the sources reviewed.","Organizational commentary and linked article descriptions are identified separately from HCP views; favorable organizational wording does not increase the certainty of efficacy, safety or biomarker conclusions."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":23,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":25},"count":25,"evidence_window":{"end":"2026-10-04","start":"2024-04-20"},"retrieval_snapshot":"2026-10-31T06:49:02.092331Z","timeline":[{"count":1,"week":"2024-W16"},{"count":1,"week":"2024-W17"},{"count":1,"week":"2024-W21"},{"count":15,"week":"2024-W22"},{"count":3,"week":"2024-W37"},{"count":1,"week":"2026-W17"},{"count":1,"week":"2026-W24"},{"count":1,"week":"2026-W40"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT04940325:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT04940325:context","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-kdvaazghtt6va3aget3thnuq-3mk5x7qoa5b2n","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-kdvaazghtt6va3aget3thnuq-3mk67d2m47m2j","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-kdvaazghtt6va3aget3thnuq-3mnu53qgv5m2o","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-kdvaazghtt6va3aget3thnuq-3mnuf744d6w2i","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-qw6djsufo4wezhpoqrrmpdek-3mjteydk4yk2u","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:a96cfa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1781680430028132594:864e062a-bbbe-42fd-a2ea-7d05bf09fcb9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1783138013285093577:ae0011cc-3782-4df4-aa7e-c1a1c1c34247","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1783141600262005026:756a4cb9-200d-45cc-8870-ab9a7b588bf5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1793768821674975252:70807473-aac6-4667-b786-ff5f373a7eb7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1795158242554699919:b0571b70-01b3-4c85-b3af-abbb22963513","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1795448979708158040:6e988d1b-373b-4844-88bc-4e809b384527","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796538370849644841:b24b88d9-0939-4189-9483-7821c6f8bb8b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796541390362694071:c2df9d60-604a-43c5-8247-3d647ecfd0d9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796628080611532806:f9bd6720-1269-460b-b3b9-260bc698ae83","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796634234599203271:5161cdb1-833a-4658-b050-620a8fae2840","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796634418091638792:cdac782d-7dd6-41e9-8e2c-278ff673fbb4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796634537004339263:511f6aee-df3f-4866-9367-67e796428577","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796634967579005074:503538fe-45e6-44f4-a4f3-7b510ccd584d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796635526692221267:f87c606e-92b6-4ae0-b15c-32071de25f8b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796635669747380676:0b3a071e-f3e0-4d88-9215-b69d854184f3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796636218995679253:e1178a3c-2139-4cf2-9a62-64e2094f5007","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796636393344569605:b6a71297-f0bd-4d06-8f41-64664458a91c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796636664023982373:5924fc8b-7bb3-4868-96d0-655e53cef9af","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796637190107078667:be30ce76-897b-4aa5-a11d-a90fbb0af518","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796637501039198480:cbf58657-aca2-4068-ba8b-14aefaa88a22","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796638406006521974:b189ef29-4cce-4882-9cfe-a512aa2532e5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796643245977428089:51fe2598-4a58-4307-b2a8-c4752e055a6c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796643455675904436:e0787bed-b582-430a-96ce-4337b9c9ad29","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796653584840335386:2b10c5bc-d13c-4c1d-9e60-16f250a299fa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796659906918887510:223a3533-99e0-44c3-9608-f9b28b5929a5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796660491248406856:11403bc8-3226-4a51-8323-a2ed91e8e71f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796660599356567775:61e7fc5b-2d4d-483d-b9b9-92d682d7eb99","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796731512651432433:0d99ca3b-df85-4de7-b95f-e6429c9046b4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796778524461699167:3d66dbd1-b8d7-4702-9995-69b477c1f511","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796935835834884386:503f3ca1-f1e4-469a-a091-e1ac298c5f79","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796958620808077565:3cf471df-9f1c-4761-a399-e8a90541f84f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1804849131992789314:b11bb2bd-f563-4e52-8405-fed80efa4fd6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1813913116167569533:a736e159-051e-4762-a40d-383058ed6472","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1820071189529706594:97396952-9c17-4da5-b751-f9d33019da9b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835224903802339491:328e0ec5-7abe-4047-9d7d-c4b20fb26851","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835259452687052848:4902277a-a7a0-4fbc-bfe8-c5b7d1e6167f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1846530789703348315:478d2fe1-f9ad-43c3-be90-0d1bc4f8151e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1849867252830748857:b0b34974-eb9a-4303-bfbd-6b2789225f91","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1856082224505921688:c74322db-2273-483b-96ab-718a5f29e952","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2046123881488867578:286f11f8-e851-4e33-9672-11064deeb7f5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2046339069861315059:6545428f-67d3-4b97-8b26-1a215b1c28f1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2047102545471090756:7f528f7d-39f8-4b1c-b8d7-b58228d7ce38","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2047319927158448634:51f042ea-dae6-410c-9d12-619a8c9ac218","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2053195942061363600:43a835ec-87bb-4f4f-a358-a41b39e28cdf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2064134777880686783:0c58c02a-6083-4f13-93dd-6fd474ded2d7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2064351965661090016:3d99ba27-baa7-443a-b1a5-b5dc10189b34","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2106775483614408806:183c626b-de01-48e6-b94a-7516e04215e3","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:0uSMnyBHzs8","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:kLz_bzn2wiM","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":5,"linkedin_post":0,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":47,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":55},"count":55,"evidence_window":{"end":"2026-10-04","start":"2024-04-20"},"retrieval_snapshot":"2026-10-31T06:49:02.575549Z","timeline":[{"count":1,"week":"2024-W16"},{"count":2,"week":"2024-W17"},{"count":1,"week":"2024-W21"},{"count":27,"week":"2024-W22"},{"count":1,"week":"2024-W25"},{"count":1,"week":"2024-W29"},{"count":1,"week":"2024-W31"},{"count":3,"week":"2024-W37"},{"count":1,"week":"2024-W42"},{"count":1,"week":"2024-W43"},{"count":1,"week":"2024-W46"},{"count":1,"week":"2026-W12"},{"count":1,"week":"2026-W16"},{"count":6,"week":"2026-W17"},{"count":1,"week":"2026-W19"},{"count":4,"week":"2026-W24"},{"count":1,"week":"2026-W40"}],"undated_sources":1}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":["Datroway"],"label":"datopotamab deruxtecan","slug":"datopotamab-deruxtecan"}],"indications":[{"reason":"Unmapped registry condition: Metastatic Lung Cancer","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"},{"reason":"Unmapped registry condition: Unresectable Non-small Lung Cancer","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"ICARUS-LUNG01","aliases":["ICARUS-LUNG01","Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer","Phase 2, Open Label Study of DS-1062a, an Anti-TROP-2-Antibody-Drug Conjugate (ADC), in Patients With Advanced and/or Unresectable Non-Small Cell Lung Cancer (NSCLC), With Biomarker Analysis to Characterize Response to Therapy"],"brief_title":"Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer","collaborators":["Daiichi Sankyo"],"conditions":["Metastatic Lung Cancer","Advanced Non Small Cell Lung Cancer","Unresectable Non-small Lung Cancer"],"display_condition":"advanced and/or unresectable non-small cell lung cancer","display_interventions":[["datopotamab deruxtecan"]],"enrollment":{"count":100,"type":"ACTUAL"},"interventions":[{"name":"DS-1062a","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT04940325","official_title":"Phase 2, Open Label Study of DS-1062a, an Anti-TROP-2-Antibody-Drug Conjugate (ADC), in Patients With Advanced and/or Unresectable Non-Small Cell Lung Cancer (NSCLC), With Biomarker Analysis to Characterize Response to Therapy","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE2"],"primary_completion_date":{"date":"2028-04","type":"ESTIMATED"},"primary_endpoints":[{"description":"ORR is defined as the proportion of participants who achieved a confirmed complete response (CR) or partial response (PR) observed on treatment and assessed by investigators","measure":"Evaluation of objective response rate (ORR) based on investigator assessment","timeFrame":"During treatment period, an average of 4 months"}],"registered_date":{"date":"2021-06-25","type":"ACTUAL"},"registry_last_updated":"2025-11-26","registry_url":"https://clinicaltrials.gov/study/NCT04940325","short_name":"ICARUS-LUNG01","short_name_basis":"registry_acronym","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","start_date":{"date":"2021-05-12","type":"ACTUAL"},"study_design":"interventional, na, single group, phase2","study_ids":[{"id":"2023-505924-71-00","type":"sponsor_study_id"},{"domain":"CSET Number (Gustave Roussy ID)","id":"2020/3187","type":"other"}],"study_type":"INTERVENTIONAL"}}}